Personalized Glucose Predictive and Therapy Advisory System - DIAdvisor 2

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

Assessment of an Enhanced Version of a Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor-2) for Diabetic Patients Treated by Basal-Bolus Insulin Regimens

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01512654
• Other study ID #: 8266 3
• Secondary ID: ID-RCB : 2011-A0
• Status: Completed
• Phase: N/A
• Start date: September 2008
• Est. completion date: June 2012

Study information

• Verified date: December 2014
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary purpose of this study is to see whether a tool that predict blood glucose and suggest therapy advices can help type 1 diabetic patients.

Description:

During this study, we would like to assess the efficacy in keeping blood glucose in a safe range (70-180 mg/dL) of the second generation of a Glucose Predictive and Therapy Advisory system in diabetic patients treated by basal-bolus insulin regimens using pumps or multiple daily injections. We want to compare the time spent in safe range while using the predictor and advisor outputs and when the patient is not using them. This is a randomized controlled crossover trial. Patient will come for two admissions of 3 days, one with the DIAdvisor system fully activated, and one with the prediction and advice features disabled.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: June 2012
• Est. primary completion date: February 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Patient must be aged between 18 (inclusive) and 70 years old

2. Patients diagnosed with type 1 or type 2 diabetes according to WHO criteria for at least one year prior to study entry

3. Patient treated by a basal-bolus insulin therapy using an external pump or multiple-daily injections. The insulin regimen has to be stable for the previous six months. NPH insulin use will not be acceptable.

4. Patient should have stable diabetes with a HbA1c between = 7.5 % and < 10.5 % with no keto-acidosis for the previous 6 months.

5. Patient must have a Body Mass Index (BMI) lower than 35 Kg/m²

6. Patient must be willing to undergo all study procedures

7. Patient must be affiliated or beneficiary of a social medical insurance

8. Patient has signed informed consent form prior to study entry

Exclusion Criteria:

1. Patient is pregnant, or breast feeding during the period of the study

2. Patient has impaired renal function with a creatinine blood concentration over 150 µmol/L

3. Patient has a liver disease (ALAT, ASAT > 2 x upper limit of normal range)

4. Patient is treated by sulfamides, GLP-1 analogues, DPP-IV inhibitors or glitazones

5. Alcohol or drug addiction, as identified by investigator during screening visit

6. Allergy to sensors or one of their components

7. Manifest psychological disorders

8. Patient health status is not compatible with physical exercise

9. Patient is actively enrolled in another clinical trial or was part of study within 30 days

10. Persons deprived of freedom, adults protected by law or vulnerable persons

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Diabetes Mellitus, Type 2

Intervention

Device:
• Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)
Glucose predictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
• Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)
Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.

Locations

Country	Name	City	State
Czechia	Institute for Clinical and Experimental Medicine	Prague
France	Montpellier University Hospital	Montpellier
Italy	Universita Degli Studi di Padova	Padova

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Countries where clinical trial is conducted

Czechia,  France,  Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of total time spent by patients in safe range (70-180mg/dL)	The primary endpoint is the percentage of total time spent by patients in safe range (70-180mg/dL). A clinically significant benefit will be reached if an increase of at least 10% of total time in range is obtained while using DIAdvisor-2.	during 3 days with DIAdvisor 2
Secondary	Percentage of total time spent in hypoglycemia (< 70 mg/dL)		during 3 days with DIAdvisor 2
Secondary	Percentage of total of time spent in hyperglycemia (>180 mg/dL)		during 3 days with DIAdvisor 2
Secondary	Mean of YSI blood glucose during total period, night time and meal periods		during the two 3 days-hospitalizations
Secondary	Percentage paired glucose values	Percentage paired glucose values: Predicted glucose t+20min vs. real glucose t to t+20min in A&B zones of EGA > 80% AND < 5% in E zone of EGA	during 3 days with DIAdvisor 2
Secondary	Coherence between system advices and physician recommendations > 0.80		during 3 days with DIAdvisor 2
Secondary	Score of patient survey regarding the acceptability of DIAdvisor-2 system		during 3 days with DIAdvisor 2